Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06114511Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BL-M07D1 in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended Phase II Dose and Objective Response Rate. Started Apr 2024; status: active, not recruiting.
02
Drugs
BL-M07D1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06114511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114511.